CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum

About this update from Cns Pharmaceuticals, Inc.

Webcast presentation on Wednesday, September 25 th at 1:55 PM CEST HOUSTON, TX / ACCESSWIRE / September 23, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco , Chief Executive Officer of CNS Pharmaceuticals will present at the 24th Annual Biotech in Europe Forum on Wednesday, September 25, 2024 at 1:55 PM CEST in Basel, Switzerland . In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website . A video webcast of the presentation will be available on demand for those registered to attend the event and can be accessed through the conference presenters portal . About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. For more information, please visit www.CNSPharma.com , and connect with the Company on X , Facebook , and LinkedIn . CONTACTS: Investor Relations Contact JTC Team, LLC Jenene Thomas 908-824-0775 [email protected] SOURCE: CNS Pharmaceuticals, Inc. View the original press release on accesswire.com

View stock analysis, news, and events for Cns Pharmaceuticals, Inc.